• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. rer. nat. Gerald Willlimsky

Cooperation Unit for Experimental and Translational Cancer Immunology
Institute of Immunology
Charité - Universitätsmedizin Berlin and German Cancer Research Center (DKFZ Heidelberg)

Campus Berlin-Buch
Haus 31.1
Robert-Rössle-Straße 10
13125 Berlin
Tel: +49 30 9406 1242
Fax: +49 30 450 751 3607


Scientific Scope

Research activities include the establishment of experimental cancer models in order to analyze cancer-host interactions, mechanisms involved in tumor rejection and to improve the efficacy of adoptive T cell therapy against various cancer. Novel therapeutic human T cell receptors to target cancer and virus antigens are identified and TCR gene therapy will be employed in the clinic.

Selected References

  • Hoser D, Schön C, Loddenkemper C, Lohneis P, Kühl AA, Sommermann T, Blankenstein T, Willimsky G. Oncogene-specific T cells fails to eradicate lymphoma-initiating B cells in mice. Blood. 2018; 132:924-934.
  • Schmidt K, Keller C, Kühl AA, Textor A, Seifert U, Blankenstein T, Willimsky* G, Kloetzel* PM. 2018. ERAP1-dependent antigen cross-presentation determines efficacy of adoptive T cell therapy in mice. Cancer Res. 78:3243-3254. (*equal contribution).
  • Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, and Blankenstein T. 2013. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest 123:1032-1043.
  • Willimsky G, Czéh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T. 2008. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 205:1687-1700.
  • Willimsky G, Blankenstein T. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146.